TRI102 — Competitive Intelligence Brief

TRI102 (TRI102) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin-norepinephrine reuptake inhibitor (SNRI). Area: Depression.

phase 3 Serotonin-norepinephrine reuptake inhibitor (SNRI) Depression Small molecule

Target snapshot

TRI102 (TRI102) — Tris Pharma, Inc.. TRI102 is a medication that works by inhibiting the reuptake of serotonin and norepinephrine.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TRI102 TARGET	TRI102	Tris Pharma, Inc.	phase 3	Serotonin-norepinephrine reuptake inhibitor (SNRI)
Pristiq	Desvenlafaxine Succinate	Pfizer	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin and norepinephrine reuptake	2008-01-01
Effexor	Venlafaxine Hydrochloride	Pfizer	marketed	Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)	Serotonin and norepinephrine reuptake transporters	1993-01-01
Venlafaxine IR and Venlafaxine XR	Venlafaxine IR and Venlafaxine XR	North Dakota State University	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT) and norepinephrine transporter (NET)
VenlafaxineXR	VenlafaxineXR	National Institute of Mental Health (NIMH)	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT); Norepinephrine transporter (NET)
venlafaxine (Effexor)	venlafaxine (Effexor)	National Institute of Mental Health (NIMH)	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT, weak)
Aripiprazole + desvenlafaxine succinate sustained release	Aripiprazole + desvenlafaxine succinate sustained release	Pfizer	marketed	Atypical antipsychotic + serotonin-norepinephrine reuptake inhibitor (SNRI) combination	Dopamine D2/D3 receptors (aripiprazole); serotonin transporter (SERT) and norepinephrine transporter (NET) (desvenlafaxine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin-norepinephrine reuptake inhibitor (SNRI) class)

1. Pfizer · 3 drugs in this class
2. Wyeth is now a wholly owned subsidiary of Pfizer · 3 drugs in this class
3. National Institute of Mental Health (NIMH) · 2 drugs in this class
4. Zhejiang Huahai Pharmaceutical Co., Ltd. · 2 drugs in this class
5. Eli Lilly and Company · 2 drugs in this class
6. New York State Psychiatric Institute · 1 drug in this class
7. North Dakota State University · 1 drug in this class
8. Ministry of Health & Welfare, Korea · 1 drug in this class
9. Purdue Pharma, Canada · 1 drug in this class
10. Shanghai Mental Health Center · 1 drug in this class